keyword
MENU ▼
Read by QxMD icon Read
search

Lipid guidelines

keyword
https://www.readbyqxmd.com/read/27914698/under-prescription-of-statins-in-patients-with-non-alcoholic-fatty-liver-disease
#1
M Del Ben, F Baratta, L Polimeni, D Pastori, L Loffredo, M Averna, F Violi, F Angelico
BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders...
September 28, 2016: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/27913073/attainment-of-ldl-cholesterol-treatment-goals-in-children-and-adolescents-with-familial-hypercholesterolemia-the-safeheart-follow-up-registry
#2
Adriana Saltijeral, Leopoldo Pérez de Isla, Rodrigo Alonso, Ovidio Muñiz, José Luis Díaz-Díaz, Francisco Fuentes, Nelva Mata, Raimundo de Andrés, Gonzalo Díaz-Soto, José Pastor, José Miguel Pinilla, Daniel Zambón, Xavier Pinto, Lina Badimón, Pedro Mata
INTRODUCTION AND OBJECTIVES: Little is known about the characteristics of persons with familial hypercholesterolemia (FH) younger than 18 years, the lipid-lowering therapy used in these patients, and the lipid goals reached in real life. Our aim was to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients younger than 18 years enrolled in a large national registry. METHODS: We analyzed patients younger than 18 years enrolled in a large ongoing registry of molecularly-defined patients with FH in Spain...
November 29, 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27911408/defining-substrate-specificities-for-lipase-and-phospholipase-candidates
#3
Diana X Sahonero-Canavesi, Maritza Zavaleta-Pastor, Lourdes Martínez-Aguilar, Isabel M López-Lara, Otto Geiger
Microorganisms produce a wide spectrum of (phospho)lipases that are secreted in order to make external substrates available for the organism. Alternatively, other (phospho)lipases may be physically associated with the producing organism causing a turnover of intrinsic lipids and frequently giving rise to a remodeling of the cellular membranes. Although potential (phospho)lipases can be predicted with a number of algorithms when the gene/protein sequence is available, experimental proof of the enzyme activities, substrate specificities, and potential physiological functions has frequently not been obtained...
November 23, 2016: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/27909694/2015-clinical-practice-guidelines-for-the-management-of-dyslipidemia-in-the-philippines-executive-summary-dyslipidemia-guidelines-2015
#4
Adriel E Guerrero
The Philippine Heart Association, the Philippine Lipid and Atherosclerosis Society, and the Philippine Society of Endocrinology, Diabetes, and Metabolism, collaborated to develop the 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines (2015 CPG). These guidelines are meant to update the 2005 Clinical Practice Guidelines on the Management of Dyslipidemia in the Philippines (2005 CPG). A panel of experts in the fields of dyslipidemia, cardiology, endocrinology and epidemiology were assembled to comprise the technical research committee (TRC) tasked to review available clinical evidence on dyslipidemia management...
October 2016: ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology
https://www.readbyqxmd.com/read/27903381/-thinking-on-principle-of-lipid-lowering-in-china-lipid-guideline
#5
S P Zhao
No abstract text is available yet for this article.
October 24, 2016: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/27901325/asymptomatic-carotid-artery-stenosis-who-should-be-screened-who-should-be-treated-and-how-should-we-treat-them
#6
Djurre D DE Waard, Dylan Morris, Gert J DE Borst, Richard Bulbulia, Alison Halliday
Although stopping smoking, lowering blood pressure and reducing lipid levels will reduce global stroke risk and cardiovascular mortality, these remain leading causes of death and disability especially in ageing populations. Further prevention strategies are needed and, in the first part of this review, we explore the potential benefits of appropriate screening for carotid artery disease to reduce stroke and identify those who may have related cardiac disease. Although whole-population carotid screening is an inefficient and costly means of identifying candidates with tight carotid stenosis who might warrant intervention, it can identify many people with lower levels of stenosis who may benefit from cardiovascular risk reducing medications...
November 30, 2016: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/27900570/concomitant-use-of-statins-in-tocilizumab-treated-patients-with-rheumatoid-arthritis-a-post-hoc-analysis
#7
Martin Soubrier, Jinglan Pei, Frédérick Durand, Lars Gullestad, Ani John
INTRODUCTION: Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin use and subsequent changes in lipid parameters in patients with RA treated with intravenous or subcutaneous TCZ (TCZ-IV or TCZ-SC) over 2 years of treatment...
November 29, 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27899853/four-statin-benefit-groups-defined-by-the-2013-acc-aha-new-cholesterol-guideline-are-characterized-by-increased-plasma-level-of-electronegative-low-density-lipoprotein
#8
Chih-Sheng Chu, Liang-Yin Ke, Hua-Chen Chan, Hsiu-Chua Chan, Chih-Chieh Chen, Kai-Hung Cheng, Hsiang-Chun Lee, Hsuan-Fu Kuo, Ching-Tang Chang, Kuan-Cheng Chang, Sheng-Hsiung Sheu, Chu-Huang Chen, Wen-Ter Lai
BACKGROUND: Significantly higher cytotoxic and thrombogenic human electronegative low-density lipoprotein (LDL), or L5, has been found in patients with stable coronary artery disease and acute coronary syndrome. We hypothesized that the statin-benefit groups (SBGs) defined by the new cholesterol guideline were of higher electronegative L5. METHODS: In total, 62 hyperlipidemia patients (mean age 59.4 ± 10.5, M/F 40/22) were retrospectively divided into SBGs (n = 44) and N-SBGs (n = 18)...
November 2016: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27888640/chronotherapy-versus-conventional-statins-therapy-for-the-treatment-of-hyperlipidaemia
#9
REVIEW
Jose Manuel Izquierdo-Palomares, Jesus Maria Fernandez-Tabera, Maria N Plana, Almudena Añino Alba, Pablo Gómez Álvarez, Inmaculada Fernandez-Esteban, Luis Carlos Saiz, Pilar Martin-Carrillo, Óscar Pinar López
BACKGROUND: Elevated levels of total cholesterol and low-density lipoprotein play an important role in the development of atheromas and, therefore, in cardiovascular diseases. Cholesterol biosynthesis follows a circadian rhythm and is principally produced at night (between 12:00 am and 6:00 am). The adjustment of hypolipaemic therapy to biologic rhythms is known as chronotherapy. Chronotherapy is based on the idea that medication can have different effects depending on the hour at which it is taken...
November 26, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27888600/-darunavir-cobicistat-monotherapy-experience-in-a-tertiary-hospital
#10
L Yunquera-Romero, R Asensi-Díez, J C Del Rio-Valencia, I Muñoz-Castillo, M A Castaño-Carracedo
OBJECTIVE: Ritonavir-boosted protease inhibitor (IP/r) monotherapy: darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pretreated patients to prevent toxicity associated with nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), reduce costs and simplify antiretroviral treatment. To start IP/r monotherapy, according to GESIDA guidelines 2016, patients need to meet the following criteria: absence of chronic hepatitis B, plasma viral load <50 copies/ mL for at least 6 months and absence of protease inhibitors mutations or previous virologic failures to IP/r...
December 2016: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/27880755/-spanish-adaptation-of-the-2016-european-guidelines-on-cardiovascular-disease-prevention-in-clinical-practice
#11
Miguel Angel Royo-Bordonada, Pedro Armario, José María Lobos Bejarano, Juan Pedro-Botet, Fernando Villar Álvarez, Roberto Elosua, Carlos Brotons Cuixart, Olga Cortés, Benilde Serrano, Miguel Camafort Babkowski, Antonio Gil Núñez, Antonio Pérez, Antonio Maiques, Ana de Santiago Nocito, Almudena Castro, Eduardo Alegría, Ciro Baeza, María Herranz, Susana Sans, Pilar Campos
The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk...
November 24, 2016: Revista Española de Salud Pública
https://www.readbyqxmd.com/read/27865998/intensive-ldl-cholesterol-lowering-therapy-and-neurocognitive-function
#12
REVIEW
Maciej Banach, Manfredi Rizzo, Dragana Nikolic, George Howard, VirginiaJ Howard, DimitriP Mikhailidis
The key lipid-lowering target is to achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) levels, usually by using statins. The new treatment strategies for lipid-lowering therapy include using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as an exciting approach to reduce residual risk of cardiovascular diseases (CVD). However, concerns about possible adverse effects, including neurocognitive disorders, were issued by the Food and Drug Administration (FDA). The current disputable evidence does not allow definite conclusions as to whether statins contribute to, or cause, clinically meaningful cognitive impairment...
November 16, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27864237/effect-of-selected-clinical-trial-publication-on-adjunctive-nonstatin-medication-prescribing-in-the-veterans-health-administration-system
#13
Krystal S Titus-Rains, Matthew A Cantrell, Jason A Egge, Bruce Alexander, Robert F Shaw, Tami R Argo
PURPOSE: The question of whether publication of selected clinical trials is temporally followed by changes in prescribing of adjunctive lipid-lowering medications was evaluated. METHODS: In this retrospective preanalysis and postanalysis, Veterans Health Administration (VHA) patients 18 years or older who received a new or renewed order for any lipid-lowering medication between April 2, 2004, and September 2, 2014, were included. This period was chosen based on the publication dates of three trials investigating the efficacy of nonstatin medications: Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia (ENHANCE, April 3, 2008), Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (ACCORD Lipid, March 14, 2010), and Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy (AIM-HIGH, December 15, 2011)...
December 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27864236/evaluation-of-adherence-to-current-guidelines-for-treatment-of-hyperlipidemia-in-adults-in-an-outpatient-setting
#14
Christina Ng, Philip Chung, Yuliana Toderika, Angela Cheng-Lai
PURPOSE: Adherence to the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline at an outpatient clinic was evaluated. METHODS: This retrospective chart review study was conducted from December 1, 2013, through November 30, 2014, at an urban outpatient clinic. Estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk was calculated based on the pooled cohort equation for all patients. Patients were categorized into one of four statin-benefit groups, in descending order of ASCVD risk...
December 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27859433/guideline-based-statin-lipid-lowering-therapy-eligibility-for-primary-prevention-and-accuracy-of-coronary-artery-calcium-and-clinical-cardiovascular-events-the-multi-ethnic-study-of-atherosclerosis-mesa
#15
Peter Flueckiger, Waqas Qureshi, Erin D Michos, Michael Blaha, Gregory Burke, Veit Sandfort, David Herrington, Joseph Yeboah
BACKGROUND: With multiple cholesterol guidelines, we evaluated the accuracy of recommended statin therapy on identifying coronary artery calcium (CAC) and cardiovascular disease (CVD) events by 2004 NCEP/ ATP III, 2016 ESC/EAS, and 2013 ACC/AHA guidelines. HYPOTHESIS: ACC/AHA guidelines are more accurate in identifying persons at risk for CVD. METHODS: 5002/6814 participants age <75 years and free of CVD were included. CAC categories (>0, ≥100, and ≥300) and 10 years of CVD outcomes were considered...
November 12, 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/27856518/a-consensus-statement-on-lipid-management-after-acute-coronary-syndrome
#16
François Schiele, Michel Farnier, Michel Krempf, Eric Bruckert, Jean Ferrières
In patients admitted for acute coronary syndrome (ACS), the guidelines of the European Society of Cardiology give a Class I, Level A recommendation for the prescription of high-intensity statins to be initiated as early as possible, regardless of the low-density lipoprotein cholesterol (LDL-C) level. Although statins are widely prescribed after ACS, the intensity of therapy and the proportion of patients achieving target LDL-C values are often not in line with recommendations due to a lack of compliance with guidelines by the physicians, a lack of compliance with treatment or poor tolerance by patients, and poor dose adaptation...
November 17, 2016: European Heart Journal. Acute Cardiovascular Care
https://www.readbyqxmd.com/read/27853916/comparing-strategies-for-lipid-lowering-in-argentina-an-analysis-from-the-cvd-policy-model-argentina
#17
Jonatan Konfino, Alicia Fernandez, Joanne Penko, Antoinette Mason, Eugenio Martinez, Pamela Coxson, David Heller, Andrew Moran, Kirsten Bibbins-Domingo, Eliseo J Pérez-Stable, Raul Mejía
INTRODUCTION: In Argentina, the national guidelines for lipid control emphasize the use of relatively inexpensive low- or moderate-potency statins by patients at high risk (>20 %) of a cardiovascular event. The objective of this study was to compare the impact and costs of the current national CVD prevention guidelines with regard to morbidity and mortality in Argentina with the impact and costs of three strategies that incorporate high-potency statins. METHODS: We used the CVD Policy Model-Argentina to model the proposed interventions...
November 16, 2016: Journal of General Internal Medicine
https://www.readbyqxmd.com/read/27845333/habitual-coffee-consumption-and-risk-of-type-2-diabetes-ischemic-heart-disease-depression-and-alzheimer-s-disease-a-mendelian-randomization-study
#18
Man Ki Kwok, Gabriel M Leung, C Mary Schooling
Observationally, coffee is inversely associated with type 2 diabetes mellitus (T2DM), depression and Alzheimer's disease, but not ischemic heart disease (IHD). Coffee features as possibly protective in the 2015 Dietary Guidelines for Americans. Short-term trials suggest coffee has neutral effect on most glycemic traits, but raises lipids and adiponectin. To clarify we compared T2DM, depression, Alzheimer's disease, and IHD and its risk factors by genetically predicted coffee consumption using two-sample Mendelian randomization applied to large extensively genotyped case-control and cross-sectional studies...
November 15, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27843182/association-between-components-of-metabolic-syndrome-and-prostatic-enlargement-an-indian-perspective
#19
P R Nandy, Sabyasachi Saha
BACKGROUND: To find association between prostate gland volume to components of the metabolic syndrome. METHODS: Cross-sectional, observational study in a tertiary care hospital of the Armed Forces of India. A total of 115 male patients aged 50-65 years attending the Urology OPD between Jan 2014 and July 2015 with lower urinary tract symptoms (LUTS) were included. Men with known malignant disease including carcinoma prostate, those on medical management for BPH and individuals with previous history of surgery related to urinary bladder/prostate were excluded...
October 2016: Medical Journal, Armed Forces India
https://www.readbyqxmd.com/read/27835069/health-effects-of-metoprolol-in-epibenthic-and-endobenthic-invertebrates-a-basis-to-validate-future-in-vitro-biotests-for-effect-based-biomonitoring
#20
Dirk Jungmann, Kristin Berg, Andreas Dieterich, Martin Frank, Tonya Gräf, Marco Scheurer, Simon Schwarz, Carmen Siewert, Matthias Oetken
The aim of this study was to determine the effect data for metoprolol as a model substance for beta-blockers in aquatic invertebrates. The results will be used as a basis for the validation of future mode of action-based in vitro test systems targeting this class of pharmaceuticals. Effects of metoprolol were investigated in two autochthonous species with high relevance in stream ecology: the amphipod Gammarus fossarum and the oligochaete Lumbriculus variegatus. Mortality in G. fossarum was not observed in acute toxicity testing (48 h), and a significant increase of mortality at 45 mg/L was found when amphipods were exposed chronically (40 days)...
November 11, 2016: Journal of Environmental Science and Health. Part A, Toxic/hazardous Substances & Environmental Engineering
keyword
keyword
36499
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"